Press Releases

Press Releases

    Date Title View
    10/23/20
    Summary ToggleHorizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
    PDF Version
    10/22/20
    Summary ToggleNew Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
    PDF Version
    10/20/20
    Summary ToggleHorizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
    PDF Version
    10/16/20
    Summary ToggleFORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
    PDF Version
    10/14/20
    Summary ToggleTEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
    PDF Version
    10/08/20
    Summary ToggleNew Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
    PDF Version
    10/08/20
    Summary ToggleHorizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
    PDF Version
    10/07/20
    Summary ToggleHorizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For
    PDF Version
    10/05/20
    Summary ToggleHorizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
    PDF Version
    10/01/20
    Summary ToggleHorizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
    PDF Version
    Displaying 21 - 30 of 551 results